Compare American Airlines Group Inc (AAL) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Airlines Group Inc vs BioNTech SE - ADR — how do they compare? American Airlines Group Inc trades at $15.01 (market cap $10.55B), while BioNTech SE - ADR trades at $93.2 (market cap $23.31B). The key difference: BioNTech SE - ADR is far larger — about 2.2× American Airlines Group Inc's market cap, and American Airlines Group Inc is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| AAL | BNTX | |
|---|---|---|
Market Cap | $10.55B | $23.31B |
Sector | Industrials | Health |
52-Week High | $18.15 | $119.34 |
52-Week Low | $10.18 | $83.89 |
Enterprise Value | $38.51B | $6.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAL trades at $15.00, down 5.9% in the last 24 hours, with technical indicators signaling a bearish trend near support at $14. The company reported mixed earnings, beating estimates in Q1 and Q2 2026 but missing in Q4 2025, with revenue growth to $54.63 billion in 2025. However, net income margin remains negative at -0.56%, and high debt levels persist despite a declining trend.
AAL's outlook is cautious; while analyst consensus is a buy with a $19.63 price target, risks include volatile fuel costs, leverage, and thin profitability. The stock offers potential upside if premium revenue growth sustains, but investors face headwinds from operational margins and economic sensitivity.
BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.
The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Airlines Group Inc
American Airlines is the world's largest airline by scheduled revenue passenger miles. The firm's major hubs are Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. After completing a major fleet renewal, the company has the youngest fleet of U.S. legacy carriers.
Read more on AAL →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
